Breast Cancer News
In this section, access cutting-edge breast cancer news on treatment updates, emerging therapies, study results and other medical and quality-of-life issues important to you.
MARIANNE Trial Shows T-DM1 Works About As Well As Standard First Treatment for HER2-Positive Metastatic Breast Cancer
At the end of 2014, the pharmaceutical company Genentech announced results from the phase III MARIANNE trial. These results show that T-DM1, with or without pertuzumab, works about as well as, but not significantly better than, the standard treatment for people newly diagnosed with HER2-positive metastatic breast cancer. Both T-DM1 and pertuzumab are sold by Genentech. The final results of MARIANNE will be presented at a future medical meeting and are not yet published in a medical journal.
The largest study of long-term breast cancer treatment using methods to stop estrogen production in premenopausal women with hormone receptor-positive disease has found what one of its authors calls “practice-changing” results for certain women.
Researchers found that immediate breast reconstruction, surgery to rebuild the breast done at the same time as mastectomy, is most likely to be used by young women in big cities who have private insurance and few chronic medical problems. Overall though, more women do NOT have their breasts rebuilt at that time.
Highlights from the annual San Antonio Breast Cancer Symposium held December 9-13, 2014 including presentation of results from a new survey conducted by Living Beyond Breast Cancer on the psychosocial needs of women with triple-negative breast cancer.
A recent small study found that electroacupuncture significantly lessened fatigue, anxiety and depression among postmenopausal woman with aromatase inhibitor-related joint pain.
After looking at information from seven studies involving T-DM1 (Kadcyla), researchers found that severe side effects were uncommon. If they did occur, they were usually manageable.
At the European Society for Medical Oncology 2014 Congress, in Madrid, in late September, Researchers presented expanded results from the ALTTO trial. These results show trastuzumab alone is more effective than lapatinib alone for early-stage, HER2-positive breast cancer.
Researchers with the AZURE trial found that giving the bone strengthening medicine zoledronic acid (Zometa) after standard treatment for early-stage breast cancer lessened the chance of cancer returning in postmenopausal women. It also lessened the chance of bone problems in all women.
A study of young women diagnosed with stage I-III breast cancer using traditional staging methods found that later PET/CT scans changed 21 percent of those diagnoses to stage III or IV.
Researchers say if a woman is obese before, shortly after or more than a year after being diagnosed with breast cancer, her risk of dying from cancer or from any cause is higher than that of a woman with breast cancer who is a healthy weight.